Evidence in decision-making in the context of COVID-19 in Latin AmericaResearch article Published on 2022-10-012022-10-05 Journal: The Lancet Regional Health - Americas [Category] 진단, [키워드] Analysis characterized Community Corticosteroids country COVID-19 COVID-19 pandemic Decision-making diagnostic test eight Evidence facilitate finding funding Grounding hydroxychloroquine/chloroquine identify International Intervention Ivermectin Latin Latin America limitation majority methodology mitigate National NPI NPIs objective outcome rapid response reported risk of infection systematic review Travel treat understanding Variation was used [DOI] 10.1016/j.lana.2022.100322 [Article Type] Research article
Ivermectin role in COVID-19 treatment (IRICT): single-center, adaptive, randomized, double-blind, placebo-controlled, clinical trialRandomized Controlled Trial Published on 2022-10-012023-07-09 Journal: Expert review of anti-infective therapy [Category] COVID19(2023년), [키워드] clinical trial COVID-19 Efficacy Hydroxychloroquine Ivermectin Safety [DOI] 10.1080/14787210.2022.2098113 [Article Type] Randomized Controlled Trial
In silico evaluation of food-derived carotenoids against SARS-CoV-2 drug targets: Crocin is a promising dietary supplement candidate for COVID-19Article Published on 2022-09-012022-11-16 Journal: Journal of food biochemistry [Category] COVID19(2023년), SARS, 변종, [키워드] ADP-ribose antioxidant B.1.351 binding affinity binding energy carotenoid carotenoids clinical trial complex component COVID-19 COVID-19 pandemic crocin dietary supplement dietary supplement candidates docking experiment docking result drug target effective exhibited Favipiravir food-derived carotenoids globe Healthcare system Helicase in silico inhibitors inhibitory effect Inhibitory effects Ivermectin Lineage molecular molecular docking Molecular dynamics simulation multitarget inhibitors. mutant mutant spike protein performed phosphatase Preliminary data Prophylaxis protease provide receptor receptors Remdesivir Replication SARS-CoV-2 SARS-CoV-2 drug Spike protein stability suggested target target protein tested therapy Treatment variants of concern [DOI] 10.1111/jfbc.14219 PMC 바로가기
In vitro evaluation of the impact of Covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivirResearch article Published on 2022-09-012022-10-05 Journal: Chemico-biological interactions [Category] 변종, 치료제, [키워드] Activation analyzed Anti-inflammatory drugs Antibiotics Antiviral appear AUC cannabidiol carboxylesterase 1 carrier CES1 clearance clinical study COVID-19 Dexamethasone enzyme evaluate evaluated fraction G143E hospitalized patient hydrolysis Hydroxychloroquine impairment in vitro in vitro study in vivo indicated individual inhibit inhibitor Interaction Ivermectin mechanism medication metabolism nine partial inhibition pharmacokinetic polymorphism produced RDV recent reduction Remdesivir required substrates suggested therapeutic agent treating COVID-19 Treatment unlikely variant with COVID-19 [DOI] 10.1016/j.cbi.2022.110097 [Article Type] Research article
Efficacy of single-dose and double-dose ivermectin early treatment in preventing progression to hospitalization in mild COVID-19: A multi-arm, parallel-group randomized, double-blind, placebo-controlled trial경증 COVID-19에서 입원으로의 진행을 예방하는 단일 용량 및 이중 용량 이버멕틴 조기 치료의 효능: 다군, 병렬 그룹, 무작위, 이중 맹검, 위약 대조 시험Randomized Controlled Trial Published on 2022-09-012022-09-11 Journal: Respirology (Carlton, Vic.) [Category] COVID19(2023년), SARS, 임상, 치료제, [키워드] absolute difference adverse event anti-parasitic Antiviral antiviral agent Clinical course clinical trial conducted coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 infection dermatitis double-blind early treatment Efficacy enrolled evaluate Hospitalization hypertension investigated Ivermectin ivermectin group Mild mild COVID-19 mild COVID-19 patients Mild symptom mild symptoms multi-arm no significant difference parallel-group Patient Placebo placebo group placebo-controlled trial Primary outcome progression proportion proportions Randomized randomized clinical trial receive required reverse transcription reverse transcription-PCR SARS-CoV-2 severity Severity Score Single-dose statistically significant subject Tachycardia [DOI] 10.1111/resp.14318 PMC 바로가기 [Article Type] Randomized Controlled Trial
COVID-19 in Latin America and the Caribbean: Two years of the pandemic라틴 아메리카와 카리브해의 COVID-19: 전염병의 2년Review Published on 2022-09-012022-09-11 Journal: Journal of internal medicine [Category] COVID19(2023년), SARS, 변종, [키워드] catastrophic coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccination death determinant determinants drug facilitated Factor Gamma global health Healthcare systems herd immunity Hydroxychloroquine Immunity Ivermectin Lambda Latin Latin America misinformation pandemic Prevent reported SARS-CoV-2 security social distancing measures Spread Support treat vaccination variant virus while [DOI] 10.1111/joim.13499 PMC 바로가기 [Article Type] Review
The effect of ivermectin on the viral load and culture viability in early treatment of nonhospitalized patients with mild COVID-19 – a double-blind, randomized placebo-controlled trialRandomized Controlled Trial Published on 2022-09-012022-10-04 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 신약개발, 임상, 치료법, 치료제, [키워드] 95% confidence interval Anti-SARS-CoV-2 Activity antiparasitic antiviral properties COVID-19 Culture cultures cycle threshold double-blind double-blinded early treatment Endpoint evaluated Infectivity Infectivity duration Ivermectin ivermectin group less Mild multivariable logistic regression Nasopharyngeal swab negative test Odds ratio Patient patients with COVID-19 per-protocol Placebo positive primary endpoint Primary outcome randomized placebo-controlled trial reached receiving recruitment reduce reduction reflected SARS-CoV-2 screened supported the placebo group Transmission Trial viability viral cultures Viral cultures. Viral load was obtained [DOI] 10.1016/j.ijid.2022.07.003 PMC 바로가기 [Article Type] Randomized Controlled Trial
COVID-19-associated Mucormycosis: A clinico-epidemiological studyObservational Study Published on 2022-09-012022-10-05 Journal: Journal of diabetes and its complications [Category] SARS, 임상, [키워드] Admission age alkaline phosphatase Antibiotics Antifungal treatment Blood Group Chronic kidney disease COVID-19 COVID-19 illness death diabetes diagnosed disease eight enrolled epidemiological expected Follow-up Frequency hyperglycemia increase in India Ivermectin Mortality much lower Mucormycosis occurred Oxygen therapy pandemic Patient patients died Pneumonia Posaconazole positive raised required risk factor RT-PCR SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 RT-PCR serology serum creatinine significantly steroid Steroids survived the patient Treatment uncontrolled use of antibiotics ventilator was done Zinc zinc supplementation [DOI] 10.1016/j.jdiacomp.2022.108284 PMC 바로가기 [Article Type] Observational Study
Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trialRandomized Controlled Trial Published on 2022-08-262022-10-05 Journal: Trials [Category] SARS, 임상, [키워드] acute respiratory syndrome adverse event adverse events age antiparasitic drug assigned caused coronavirus coronavirus disease COVID-19 double-blind duration of hospitalization Effectiveness Efficacy enrolment Frequency group hospitalized patient Ivermectin ivermectin treatment Mild Moderate COVID-19 n=36 negativity no difference outbreak overcome pandemic Patient PCR-positive PCR-positive patient Placebo placebo-controlled placebo-controlled trial polymerase chain Primary outcome proportion Randomized Randomized controlled trial Randomly receiving reported reverse transcription RT-PCR SARS-CoV-2 Secondary endpoints secondary outcome shown Side effects significant difference single-center standard care Standard of care survival symptomatic Symptoms therapeutic Treatment Trial worsening [DOI] 10.1186/s13063-022-06649-3 PMC 바로가기 [Article Type] Randomized Controlled Trial
Potential therapeutic effects of Ivermectin in COVID-19Article Published on 2022-08-012023-07-09 Journal: Experimental Biology and Medicine [Category] COVID19(2023년), [키워드] COVID-19 hypoxia-inducible factor-alpha Importin Inflammation Ivermectin lung Pandemics SARS-CoV-2 [DOI] 10.1177/15353702221099579 PMC 바로가기